Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Tecartus (brexucabtagene autoleucel by Year
Tecartus (brexucabtagene autoleucel — MCL / ALL CAR T) — Europe sales ($M) ($M)
Gilead Sciences Tecartus (brexucabtagene autoleucel: $158M in FY2025, up 14.5% from a year earlier. That is the highest of the 8 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Tecartus (brexucabtagene autoleucel — MCL / ALL CAR T) — Europe sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 158 | +14.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 138 | +25.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 110 | +46.7% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 75 | +87.5% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 40 | +300.0% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 10 | – | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-25) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Tecartus (brexucabtagene autoleucel ($M), annual FY2018–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/onc-tecartus-eu
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.